S
Seres Therapeutics, Inc. (MCRB)
NMS – Real Time Price. Currency in USD
7.96
+0.01 (0.13%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
7.96
+0.01 (0.13%)
At close: May 12, 2026, 4:00 PM EDT
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Name | Position |
|---|---|
| Dr. Dennis M. Walling M.D. | Senior VP of Clinical Development & Head of Clinical Research |
| Dr. Matthew R. Henn Ph.D. | President & Chief Scientific Officer |
| Mr. Chris McChalicher | Executive VP & CTO |
| Mr. Richard N. Kender B.S., M.B.A. | Interim CEO & Executive Chair |
| Mr. Thomas J. DesRosier Esq., J.D. | Executive VP, Chief Legal Officer & Secretary |
| Ms. Ann Kurowski | Senior Vice President of Regulatory Affairs |
| Ms. Kelly Brady M.S. | Executive VP & COO |
| Ms. Marella Thorell CPA | Executive VP, CFO & Treasurer |
| Date | Type | Document |
|---|---|---|
| 2026-05-05 | 8-K | d155025d8k.htm |
| 2026-05-05 | 10-Q | mcrb-20260331.htm |
| 2026-04-27 | DEFA14A | ef20071345_defa14a.htm |
| 2026-03-16 | 8-K | d47103d8k.htm |
| 2026-03-12 | 10-K | mcrb-20251231.htm |
| 2026-03-02 | 8-K | d13425d8k.htm |
| 2025-11-05 | 8-K | d27174d8k.htm |
| 2025-11-05 | 10-Q | mcrb-20250930.htm |
| 2025-10-03 | 8-K | d63317d8k.htm |
| 2025-08-06 | 8-K | d930624d8k.htm |